Molecular remission at T cell level in patients with rheumatoid arthritis

Abstract While numerous disease-modifying anti-rheumatic drugs (DMARDs) have brought about a dramatic paradigm shift in the management of rheumatoid arthritis (RA), unmet needs remain, such as the small proportion of patients who achieve drug-free status. The aim of this study was to explore key mol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jun Inamo, Katsuya Suzuki, Masaru Takeshita, Yasushi Kondo, Yuumi Okuzono, Keiko Koga, Yoshiaki Kassai, Maiko Takiguchi, Rina Kurisu, Akihiko Yoshimura, Tsutomu Takeuchi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5e11e293e5ff4fb8a57943a089d52458
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e11e293e5ff4fb8a57943a089d52458
record_format	dspace
spelling	oai:doaj.org-article:5e11e293e5ff4fb8a57943a089d524582021-12-02T18:51:42ZMolecular remission at T cell level in patients with rheumatoid arthritis10.1038/s41598-021-96300-z2045-2322https://doaj.org/article/5e11e293e5ff4fb8a57943a089d524582021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96300-zhttps://doaj.org/toc/2045-2322Abstract While numerous disease-modifying anti-rheumatic drugs (DMARDs) have brought about a dramatic paradigm shift in the management of rheumatoid arthritis (RA), unmet needs remain, such as the small proportion of patients who achieve drug-free status. The aim of this study was to explore key molecules for remission at the T cell level, which are known to be deeply involved in RA pathogenesis, and investigate the disease course of patients who achieved molecular remission (MR). We enrolled a total of 46 patients with RA and 10 healthy controls (HCs). We performed gene expression profiling and selected remission signature genes in CD4+ T cells and CD8+ T cells from patients with RA using machine learning methods. In addition, we investigated the benefits of achieving MR on disease control. We identified 9 and 23 genes that were associated with clinical remission in CD4+ and CD8+ T cells, respectively. Principal component analysis (PCA) demonstrated that their expression profiling was similar to those in HCs. For the remission signature genes in CD4+ T cells, the PCA result was reproduced using a validation cohort, indicating the robustness of these genes. A trend toward better disease control was observed during 12 months of follow-up in patients treated with tocilizumab in deep MR compared with those in non-deep MR, although the difference was not significant. The current study will promote our understanding of the molecular mechanisms necessary to achieve deep remission during the management of RA.Jun InamoKatsuya SuzukiMasaru TakeshitaYasushi KondoYuumi OkuzonoKeiko KogaYoshiaki KassaiMaiko TakiguchiRina KurisuAkihiko YoshimuraTsutomu TakeuchiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jun Inamo Katsuya Suzuki Masaru Takeshita Yasushi Kondo Yuumi Okuzono Keiko Koga Yoshiaki Kassai Maiko Takiguchi Rina Kurisu Akihiko Yoshimura Tsutomu Takeuchi Molecular remission at T cell level in patients with rheumatoid arthritis
description	Abstract While numerous disease-modifying anti-rheumatic drugs (DMARDs) have brought about a dramatic paradigm shift in the management of rheumatoid arthritis (RA), unmet needs remain, such as the small proportion of patients who achieve drug-free status. The aim of this study was to explore key molecules for remission at the T cell level, which are known to be deeply involved in RA pathogenesis, and investigate the disease course of patients who achieved molecular remission (MR). We enrolled a total of 46 patients with RA and 10 healthy controls (HCs). We performed gene expression profiling and selected remission signature genes in CD4+ T cells and CD8+ T cells from patients with RA using machine learning methods. In addition, we investigated the benefits of achieving MR on disease control. We identified 9 and 23 genes that were associated with clinical remission in CD4+ and CD8+ T cells, respectively. Principal component analysis (PCA) demonstrated that their expression profiling was similar to those in HCs. For the remission signature genes in CD4+ T cells, the PCA result was reproduced using a validation cohort, indicating the robustness of these genes. A trend toward better disease control was observed during 12 months of follow-up in patients treated with tocilizumab in deep MR compared with those in non-deep MR, although the difference was not significant. The current study will promote our understanding of the molecular mechanisms necessary to achieve deep remission during the management of RA.
format	article
author	Jun Inamo Katsuya Suzuki Masaru Takeshita Yasushi Kondo Yuumi Okuzono Keiko Koga Yoshiaki Kassai Maiko Takiguchi Rina Kurisu Akihiko Yoshimura Tsutomu Takeuchi
author_facet	Jun Inamo Katsuya Suzuki Masaru Takeshita Yasushi Kondo Yuumi Okuzono Keiko Koga Yoshiaki Kassai Maiko Takiguchi Rina Kurisu Akihiko Yoshimura Tsutomu Takeuchi
author_sort	Jun Inamo
title	Molecular remission at T cell level in patients with rheumatoid arthritis
title_short	Molecular remission at T cell level in patients with rheumatoid arthritis
title_full	Molecular remission at T cell level in patients with rheumatoid arthritis
title_fullStr	Molecular remission at T cell level in patients with rheumatoid arthritis
title_full_unstemmed	Molecular remission at T cell level in patients with rheumatoid arthritis
title_sort	molecular remission at t cell level in patients with rheumatoid arthritis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5e11e293e5ff4fb8a57943a089d52458
work_keys_str_mv	AT juninamo molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT katsuyasuzuki molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT masarutakeshita molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT yasushikondo molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT yuumiokuzono molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT keikokoga molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT yoshiakikassai molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT maikotakiguchi molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT rinakurisu molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT akihikoyoshimura molecularremissionattcelllevelinpatientswithrheumatoidarthritis AT tsutomutakeuchi molecularremissionattcelllevelinpatientswithrheumatoidarthritis
_version_	1718377387142414336

Molecular remission at T cell level in patients with rheumatoid arthritis

Ejemplares similares